Patricia L M Dahia

List of Publications by Year
in descending order

51 papers	7,420 citations	172457 29 h-index	197818 49 g-index
69 all docs	69 docs citations	69 times ranked	6671 citing authors

#	Article	IF	Citations
1	Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nature Genetics, 1997, 16, 64-67.	21.4	1,902
2	Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nature Genetics, 1997, 16, 333-334.	21.4	622
3	Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 314-318.	7.1	574
4	Clinical Presentation and Penetrance of Pheochromocytoma/Paraganglioma Syndromes. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 827-836.	3.6	560
5	Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nature Reviews Cancer, 2014, 14, 108-119.	28.4	442
6	A HIF1Î± Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas. PLoS Genetics, 2005, 1, e8.	3.5	394
7	Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nature Genetics, 2010, 42, 229-233.	21.4	364
8	MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2012, 18, 2828-2837.	7.0	277
9	Germline Dinucleotide Mutation in Codon 883 of theRETProto-Oncogene in Multiple Endocrine Neoplasia Type 2B Without Codon 918 Mutation. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3902-3904.	3.6	216
10	Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas. Nature Reviews Endocrinology, 2017, 13, 233-247.	9.6	198
11	Spectrum and Prevalence of FP/TMEM127 Gene Mutations in Pheochromocytomas and Paragangliomas. JAMA - Journal of the American Medical Association, 2010, 304, 2611.	7.4	174
12	A germline mutation of the KIF1BÎ² gene on 1p36 in a family with neural and nonneural tumors. Human Genetics, 2008, 124, 279-285.	3.8	139
13	Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas. Clinical Cancer Research, 2016, 22, 2301-2310.	7.0	136
14	A Novel Germline Mutation in BAP1 Predisposes to Familial Clear-Cell Renal Cell Carcinoma. Molecular Cancer Research, 2013, 11, 1061-1071.	3.4	135
15	RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours. Oncogene, 2001, 20, 7573-7577.	5.9	127
16	In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas. Endocrine-Related Cancer, 2013, 20, 349-359.	3.1	110
17	Novel Pheochromocytoma Susceptibility Loci Identified by Integrative Genomics. Cancer Research, 2005, 65, 9651-9658.	0.9	88
18	Allelic imbalance, including deletion ofPTEN/MMAC1, at the Cowden disease locus on 10q22-23, in hamartomas from patients with cowden syndrome and germlinePTEN mutation. , 1998, 21, 61-69.		85

#	Article	IF	Citations
19	International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. Nature Reviews Endocrinology, 2021, 17, 435-444.	9.6	80
20	Germline Dinucleotide Mutation in Codon 883 of the RETProto-Oncogene in Multiple Endocrine Neoplasia Type 2B Without Codon 918 Mutation. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3902-3904.	3.6	73
21	IDH Mutation, Competitive Inhibition of FTO, and RNA Methylation. Cancer Cell, 2017, 31, 619-620.	16.8	65
22	Evolving concepts in pheochromocytoma and paraganglioma. Current Opinion in Oncology, 2006, 18, 1-8.	2.4	64
23	D2HGDH regulates alpha-ketoglutarate levels and dioxygenase function by modulating IDH2. Nature Communications, 2015, 6, 7768.	12.8	64
24	The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma. Pancreas, 2021, 50, 469-493.	1.1	55
25	VHL Disease. Best Practice and Research in Clinical Endocrinology and Metabolism, 2010, 24, 401-413.	4.7	53
26	Penetrance and Clinical Features of Pheochromocytoma in a Six-Generation Family Carrying a Germline TMEM127 Mutation. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E308-E318.	3.6	44
27	Transcription Association of VHL and SDH Mutations Link Hypoxia and Oxidoreductase Signals in Pheochromocytomas. Annals of the New York Academy of Sciences, 2006, 1073, 208-220.	3.8	42
28	Minireview: The Busy Road to Pheochromocytomas and Paragangliomas Has a New Member, TMEM127. Endocrinology, 2011, 152, 2133-2140.	2.8	42
29	EPAS1 Mutations and Paragangliomas in Cyanotic Congenital Heart Disease. New England Journal of Medicine, 2018, 378, 1259-1261.	27.0	41
30	HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: Metastatic pheochromocytomas and paragangliomas: proceedings of the MEN2019 workshop. Endocrine-Related Cancer, 2020, 27, T41-T52.	3.1	33
31	Pheochromocytomas and Paragangliomas, Genetically Diverse and Minimalist, All at Once!. Cancer Cell, 2017, 31, 159-161.	16.8	30
32	Mutations of the Metabolic GenesIDH1,IDH2, andSDHAF2Are Not Major Determinants of the Pseudohypoxic Phenotype of Sporadic Pheochromocytomas and Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1469-1472.	3.6	25
33	The TMEM127 human tumor suppressor is a component of the mTORC1 lysosomal nutrient-sensing complex. Human Molecular Genetics, 2018, 27, 1794-1808.	2.9	18
34	Endocrine and Neuroendocrine Tumors Special Issueâ€"Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma: Do They Work?. Cancers, 2022, 14, 467.	3.7	18
35	Synonymous but Not Silent: A Synonymous VHL Variant in Exon 2 Confers Susceptibility to Familial Pheochromocytoma and von Hippel-Lindau Disease. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3826-3834.	3.6	17
36	The tumor suppressor TMEM127 regulates insulin sensitivity in a tissue-specific manner. Nature Communications, 2019, 10, 4720.	12.8	14

#	Article	IF	Citations
37	MYC Regulation of D2HGDH and L2HGDH Influences the Epigenome and Epitranscriptome. Cell Chemical Biology, 2020, 27, 538-550.e7.	5.2	14
38	Novel Hereditary Forms of Pheochromocytomas and Paragangliomas. Frontiers of Hormone Research, 2013, 41, 79-91.	1.0	13
39	Insights into Mechanisms of Pheochromocytomas and Paragangliomas Driven by Known or New Genetic Drivers. Cancers, 2021, 13, 4602.	3.7	11
40	Recognizing hypoxia in phaeochromocytomas and paragangliomas. Nature Reviews Endocrinology, 2020, 16, 191-192.	9.6	9
41	Molecular and phenotypic evaluation of a novel germline TMEM127 mutation with an uncommon clinical presentation. Endocrine-Related Cancer, 2017, 24, L79-L82.	3.1	8
42	Functional Characterization of TMEM127 Variants Reveals Novel Insights into Its Membrane Topology and Trafficking. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3142-e3156.	3.6	8
43	Genotype-Phenotype Features of Germline Variants of the TMEM127 Pheochromocytoma Susceptibility Gene: A 10-Year Update. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e350-e364.	3.6	8
44	Nextâ€generation sequencing for the genetic screening of phaeochromcytomas and paragangliomas: riding the new wave, but with caution. Clinical Endocrinology, 2014, 80, 23-24.	2.4	6
45	A Unique Case of Metastatic, Functional, Hereditary Paraganglioma Associated With anSDHC Germline Mutation. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2802-2806.	3.6	6
46	Genetic predisposition to neural crest-derived tumors: revisiting the role of KIF1B. Endocrine Connections, 2020, 9, 1042-1050.	1.9	5
47	Predictors of outcome in phaeochromocytomas and paragangliomas. F1000Research, 2017, 6, 2160.	1.6	3
48	Molecular Biology of Pheochromocytomas and Paragangliomas. , 2010, , 297-305.		2
49	Thyroid nodules of indeterminate cytology in Hispanic/Latinx patients. Head and Neck, 2022, , .	2.0	2
50	Genetic predisposition to neural crest-derived tumors: revisiting the role of KIF1B. Endocrine Connections, 2020, 9, 1042-1050.	1.9	1
51	A MYC Driven and Metabolite Executed Axis Controls the Subcellular Localization and Activity of TET DNA Hydroxylases and RNA Demethylases in B Cell Lymphomas. Blood, 2019, 134, 114-114.	1.4	0